Twist Bioscience (TWST) Jefferies Global Healthcare Conference summary

Strategic direction and growth

• Focused on scalable, profitable growth by targeting expanding markets and launching new products.

• Achieved significant revenue growth from $2.3M in 2016 to $245M in 2023, with Q2 2024 revenue at $75M and 41% gross margin.

• Revenue guidance for fiscal 2024 is $300M–$304M, with a target of 50% gross margin by Q4 2025.

• Efficient operations and a high fixed-cost, low variable-cost model improve margins as revenue scales.

• Cash management supports profitability goals, with $245M expected in the bank at year-end.

Technology and product innovation

• Proprietary silicon chip technology enables synthesis of up to 16 million oligos per day and supports DNA, RNA, and protein products.

• Miniaturization allows for massive scale and cost efficiency, with all products derived from the same platform.

• Platform supports hundreds of SKUs for diverse applications, including SynBio, NGS, Biopharma, and data storage.

• Recent advances include Express Genes, offering industry-leading speed and price competitiveness.

• Sustainability advantage: significantly lower carbon emissions per gene compared to competitors.

Market positioning and customer base

• Serves over 3,400 customers, primarily in healthcare, with significant opportunities remaining in SynBio and NGS markets.

• SynBio customers include pharma, biotech, industrial chemical, AgBio, and academic labs.

• NGS products enable diagnostic companies to perform advanced genetic analyses, with high-quality panels reducing sequencing needs.

• Biopharma Solutions offers a differentiated service combining in vivo, in vitro, and AI for drug discovery.

• Data storage business aims to commercialize DNA-based archival storage, targeting early access in 2025.